Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson

Last Updated: November 19, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,958,335

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 6,958,335 protect, and when does it expire?

Patent 6,958,335 protects GLEEVEC and is included in two NDAs.

Protection for GLEEVEC has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-four patent family members in twenty-five countries.

Summary for Patent: 6,958,335
Title: Treatment of gastrointestinal stromal tumors
Abstract:4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2- ylamino)phenyl]-benzamide of the formula I ##STR1## or a pharmaceutically acceptable salt thereof can be used in the treatment of gastrointestinal stromal tumours.
Inventor(s): Buchdunger; Elisabeth (Neuenburg, DE), Capdeville; Renaud (Riedesheim, FR), Demetri; George Daniel (Brookline, MA), Dimitrijevic; Sasa (Habsheim, FR), Druker; Brian Jay (Portland, OR), Fletcher; Jonathan A. (Brookline, MA), Heinrich; Michael C. (Lake Oswego, OR), Joensuu; Heikki (Helsinki, FI), Silberman; Sandra Leta (Randolph, NJ), Tuveson; David (Berwyn, PA)
Assignee: Novartis AG (Basel, CH) Dana-Farber Cancer Institute, Inc. (Boston, MA) Oregon Health & Science University (Portland, OR)
Application Number:10/415,015
Patent Claim Types:
see list of patent claims
Use; Compound;

Drugs Protected by US Patent 6,958,335

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Novartis GLEEVEC imatinib mesylate CAPSULE;ORAL 021335-001 May 10, 2001 DISCN Yes No   Start Trial   Start Trial Y   Start Trial
Novartis GLEEVEC imatinib mesylate CAPSULE;ORAL 021335-002 May 10, 2001 DISCN Yes No   Start Trial   Start Trial Y   Start Trial
Novartis GLEEVEC imatinib mesylate TABLET;ORAL 021588-001 Apr 18, 2003 AB RX Yes No   Start Trial   Start Trial Y   Start Trial
Novartis GLEEVEC imatinib mesylate TABLET;ORAL 021588-002 Apr 18, 2003 AB RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 6,958,335

PCT Information
PCT FiledOctober 26, 2001PCT Application Number:PCT/EP01/12442
PCT Publication Date:May 02, 2002PCT Publication Number: WO02/34727

International Family Members for US Patent 6,958,335

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 321556   Start Trial
Australia 1826202   Start Trial
Australia 2002218262   Start Trial
Brazil 0114870   Start Trial
Canada 2424470   Start Trial
China 1276754   Start Trial
China 1622808   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.